16 January 2018 - - San Diego, California-based biopharmaceutical company Ligand Pharmaceuticals Inc. (NASDAQ: LGND) has entered a worldwide OmniAb platform license agreement with Mumbai-based pharmaceutical company Glenmark Pharmaceuticals, the company said.
Under the license, Glenmark will be able to use the full OmniAb platform including OmniChicken, OmniRat, OmniMouse, and OmniFlic to discover fully human mono- and multispecific antibodies.
Ligand is eligible to receive annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody.
Glenmark will be responsible for all costs related to the programs.
OmniAb is a three-species transgenic-animal platform consisting of four different technologies used for producing mono- and multispecific human therapeutic antibodies.
The four technologies use patented technology, have broad freedom to operate and deliver fully human antibodies with high affinity, specificity, expression, solubility and stability.
Glenmark has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory disease and dermatology. The company has operations in more than 50 countries.
Ligand is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.
The company partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate revenue.